AJANTA PHARMA LTD.

NSE : AJANTPHARMBSE : 532331ISIN CODE : INE031B01049Industry : Pharmaceuticals & DrugsHouse : Vimal Agrawal
BSE2238.1054.8 (+2.51 %)
PREV CLOSE ( ) 2183.30
OPEN PRICE ( ) 2198.55
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1989
TODAY'S LOW / HIGH ( )2181.60 2240.00
52 WK LOW / HIGH ( )1154.7 2355.05
NSE2230.8537.35 (+1.7 %)
PREV CLOSE( ) 2193.50
OPEN PRICE ( ) 2179.35
BID PRICE (QTY) 2230.85 (11)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 149374
TODAY'S LOW / HIGH( ) 2173.60 2247.95
52 WK LOW / HIGH ( )1155.1 2353.95
BSE
1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Incorporation Year : 31-12 1979
Management Info
Mannalal B Agrawal - Chairman Yogesh M Agrawal - Managing Director
Registered Office

Address Ajanta House,Charkop ,Kandivali (W),
Mumbai,
Maharashtra-400067

Phone 022-66061000

Email legal.info@ajantapharma.com

Website www.ajantapharma.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX
NEWS
31Jan Cancellation Of Employee Stock Option
Please note that the Nomination and Remuneration Committee of the Board..
25Jan Ajanta Pharma informs about update on
With reference to its letter dated 19th January 2024, informing about th..
25Jan Ajanta Pharma submits intimation of re
With reference to letter dated 19th January 2024, informing about the Bo..
19Dec Ajanta Pharma informs about loss of sh
Pursuant to Regulation 39(3) and other applicable regulations of SEBI Li..
15Dec Ajanta Pharma informs about loss of sh
Pursuant to Regulation 39(3) and other applicable regulations of SEBI Li..
Financials
Rs. in Millions
QTR Dec 23 ANNUAL 23
Net Profit2201.55587.19999999999
Gross Profit 3051.4 6998.49999999999
Operating Profit 3409.18320.29999999999
Net Sales 10852.934112.7
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group
Abbott India (BSE)
 26946.00 (0.74%)
M.Cap (Rs. in Cr)57258.37
Sanofi India (BSE)
 8118.25 (2.06%)
M.Cap (Rs. in Cr)18696.83
Dr. Reddy's Lab (BSE)
 6155.15 (1.78%)
M.Cap (Rs. in Cr)102679.14
Divi's Lab (BSE)
 3436.75 (2.14%)
M.Cap (Rs. in Cr)91234.91
Glaxosmithkline Phar (BSE)
 1943.10 (3.26%)
M.Cap (Rs. in Cr)32917.29
Shareholding Pattern
PROMOTERS 66.21%
MUTUAL FUNDS/UTI 13.86%
NON-INSTITUTION 8.01%
FI/BANKS/INSURANCE 2.15%
GOVERNMENT 0%
FII 0%
ATTENTION INVESTORSKYCIPO
Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do’s & Don’t’s) in Vernacular Language :
REGISTRATION NOS.

NSE CM-INZ000234235|NSE F& O - INZ000234235, NSE CD-INZ000234235, BSE CM–INZ000234235 |BSE F & O - INZ000234235|BSE CD- INZ000234235 MCX-SX CM-INZ000234235|MCX-SX F & O - INZ000234235|MCX-SX CD-INZ000234235 NSDL - IN-DP-NSDL-319-2009ROC REG - 21-097912,CDSL : IN-DP-242-2016|SEBI-PMS: INP000007100|LEI- 3358007DLCFNHY8J2F96

Filing compliant on SCORES – Easy & quick

  • Register on SCORES portal
  • Mandatory details for filing complaints on SCORES:
    • Name
    • PAN
    • Address
    • Mobile Number
    • E-mail ID
  • Benefits:
    • i.) Effective communication
    • ii.) Speedy redressal of the grievances
INVESTOR PROTECTION

Compliance officer : Apurva Mittal, Tel No: 022-40790035,022-40790024, Mobile No: 9152943075, E-mail ID: compliance@nnmsecurities.com, cdsl@nnmsecurities.com

Investor grievance : support@nnmsecurities.com

"NNM Securities has partnered with TradingView for its charting technology. An investment and trading platform empowering users with global market data and analytical tools like Stock Screener and Economic Calendar."

Copyright © 2021 NNM Securities.com

Advanced Charts Technology Partner: TradingView

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.